Effect on CD4 T-cell count of replacing protease inhibitors in patients with successful HIV suppression

This publication has 10 references indexed in Scilit:

• Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral Suppression
  Clinical Infectious Diseases, 2002
• Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides
  AIDS, 2002
• Modulation of apoptosis by HIV protease inhibitors
  Apoptosis, 2002
• Initial Virological and Immunologic Response to Highly Active Antiretroviral Therapy Predicts Long‐Term Clinical Outcome
  Clinical Infectious Diseases, 2001
• Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA
  AIDS, 2001
• Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor–Experienced Patients With HIV-Associated Lipodystrophy
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
• Treatment of Primary Human Immunodeficiency Virus Type 1 Infection with Potent Antiretroviral Therapy Reduces Frequency of Rapid Progression to AIDS
  The Journal of Infectious Diseases, 2001
• Impact of Switching from Human Immunodeficiency Virus Type 1 Protease Inhibitors to Efavirenz in Successfully Treated Adults with Lipodystrophy
  Clinical Infectious Diseases, 2000
• Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
  AIDS, 2000
• Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
  AIDS, 1999